CryoLife, Inc. (CRY) Stock Rating Lowered by TheStreet
A number of other analysts have also issued reports on the company. Lake Street Capital increased their target price on CryoLife to $26.00 and gave the company a buy rating in a report on Wednesday, October 11th. Zacks Investment Research lowered CryoLife from a hold rating to a sell rating in a report on Tuesday, October 17th. BidaskClub lowered CryoLife from a buy rating to a hold rating in a report on Monday, July 24th. Finally, Canaccord Genuity reiterated a buy rating and set a $25.00 price objective on shares of CryoLife in a report on Monday, October 9th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of $23.63.
CryoLife (NYSE:CRY) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.08. The company had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.13 earnings per share.
In related news, Director James Benson sold 2,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total transaction of $45,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James P. Mackin sold 43,050 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total value of $950,974.50. Following the sale, the chief executive officer now owns 398,399 shares of the company’s stock, valued at $8,800,633.91. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 171,050 shares of company stock valued at $3,769,825. 6.00% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its position in CryoLife by 16.5% during the first quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock worth $517,000 after buying an additional 4,399 shares during the last quarter. Royce & Associates LP increased its position in CryoLife by 10.0% during the second quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock worth $8,682,000 after buying an additional 39,500 shares during the last quarter. Ameriprise Financial Inc. increased its position in CryoLife by 4.6% during the first quarter. Ameriprise Financial Inc. now owns 162,996 shares of the medical equipment provider’s stock worth $2,714,000 after buying an additional 7,228 shares during the last quarter. William Blair Investment Management LLC acquired a new position in CryoLife during the second quarter worth $4,517,000. Finally, Marshall Wace North America L.P. increased its position in CryoLife by 118.4% during the second quarter. Marshall Wace North America L.P. now owns 133,021 shares of the medical equipment provider’s stock worth $2,660,000 after buying an additional 72,114 shares during the last quarter. 69.01% of the stock is currently owned by hedge funds and other institutional investors.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.